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Abstract: Elevated Dicer and Drosha mRNA levels have been documented across a range of tumor types (including ovarian carcinoma) 
by a number of investigators without any demonstrable correlation with patient survival nor evidence of interference with shRNA 
processing.  A recent publication by Merritt et al. (NEJM 359(25):2641-50, 2008) reporting their findings in patients with ovarian 
carcinoma reach opposite conclusions.  Further study will be needed to resolve this issue.
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Using Affymetrix GeneChip Microarray, we recently 
documented  0.2  to  2,145  fold  Dicer  mRNA  over 
expression  normalized  to  comparator  tissue  in 
26  patients;  primarily  lung,  breast  and  colon.  In 
addition, we and others have demonstrated effective 
shRNA mediated silencing in cells with low Dicer 
expression.  Although  a  global  downregulation 
of  miRNA  (also  dependent  on  Dicer  mediated 
biogenesis) in cancer was initially reported using the 
Luminex bead-based profiling assay,1 no significant 
differences in Dicer or Drosha mRNA were detected 
in that study (n = 334 samples) nor has there since 
been any clinically based definitive linkage between 
Dicer  mRNA  levels  and  miRNA  signatures.  In  a 
comparison  of  ovarian  serous  adenocarcinoma  to 
normal  ovarian  surface  epithelium,  Drosha  was 
upregulated 2.7 fold and Dicer 1.6 fold2 without any 
association of Dicer expression with either disease-
free or overall survival. Similarly, despite confirming 
miRNA downregulation in late stage ovarian cancer, 
Zhang found no significant differences in Dicer or 
Drosha mRNA between early versus late stage disease 
or  between  epithelial  ovarian  carcinoma  cell  lines 
and  immortalized  primary  cultured  human  ovarian 
surface  epithelium.3  Nor  was  a  correlation  found 
between  Dicer  (or  Drosha)  expression  levels  and 
survival.  Moreover,  even  though  Dicer  expression 
has been shown to be low in both monocytic cell 
lines and monocytes derived from healthy donors,4 
shRNA is functionally effective in CD34+ derived 
macrophages as well as in monocytic cell lines and 
monocyte-derived macrophages (see ref. 56 and 57 
in ref. 4). The authors claim that the low levels of 
Dicer  in  these  cell  types  are  sufficient  to  support 
miRNA biogenesis. The “low” Dicer expressing cell 
lines may, therefore, have slower knockdown kinetics 
for shRNA rather than being less effective. If not, 
then miRNA levels in shRNA treated cells, a more 
biologically relevant indicator, should be lower. Yet 
Merritt et al. recently reported decreased Dicer and 
Drosha mRNA and expression in both cell lines and 
tumor  samples  from  patients  with  ovarian  cancer.5 
Sixty percent of specimens had decreased normalized 
Dicer mRNA. Furthermore, low Dicer levels were 
found to be a predictor of reduced disease-specific 
survival in multivariate analysis. Of particular interest 
was the finding that, compared to siRNA mediated 
silencing of the galectin-3 gene, poor silencing was 
achieved with shRNA in ovarian cancer cell lines with 
low versus high Dicer expression. Further evaluation 
of these contradicting results will be required.
Disclosure 
The authors report no conflicts of interest.
References
  1.  Lu  J,  Getz  G,  Miska  EA,  et al.  MicroRNA  expression  profiles  classify 
human cancers. Nature. 2005;435(7043):834–8.
  2.  Flavin RJ, Smyth PC, Finn SP, et al. Altered eIF6 and Dicer expression 
is associated with clinicopathological features in ovarian serous carcinoma 
patients. Mod Pathol. 2008;21(6):676–84.
  3.  Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations 
deregulate  microRNA  expression  in  human  epithelial  ovarian  cancer. 
Proceedings of the National Academy of Sciences of the United States of 
America. 2008;105(19):7004–9.
  4.  Klase Z, Kale P, Winograd R, et al. HIV-1 TAR element is processed by 
Dicer to yield a viral micro-RNA involved in chromatin remodeling of the 
viral LTR. BMC Mol Biol. 2007;8:63.
  5.  Merritt  WM,  Lin  YG,  Han  LY,  et al.  Dicer,  Drosha,  and  outcomes  in 
patients  with  ovarian  cancer.  The  New  England  journal  of  medicine. 
2008;359(25):2641–50.